ArticleInternational journal of genomics2026
Gut Microbiome-Metabolite Interactions Contribute to Esophageal Cancer Risk: Evidence From Mendelian Randomization and Multiomics Integration.
Article in International journal of genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gut Microbiome-Metabolite Interactions Contribute to Esophageal Cancer Risk: Evidence From Mendelian Randomization and Multiomics Integration.International journal of genomics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Growing evidence implicates gut microbiota (GM) in the pathogenesis of esophageal cancer (EC). However, the causal nature of this association-particularly the potential mediating role of circulating metabolites-remains insufficiently clarified, especially across EC subtypes. Methods: We applied a two-sample Mendelian randomization (MR) framework to investigate the causal associations of GM and blood metabolites with EC and esophageal adenocarcinoma (EAC). The primary analysis was conducted using the inverse-variance weighted method, with complementary MR approaches and genetic risk score (GRS) validation to ensure robustness. Mediation analyses were further performed to assess whether metabolites mediate the effects of GM on EC and EAC. Results: Twenty-five GM taxa showed significant associations with EC, including 11 with risk-promoting and 14 with protective effects. For EAC, 15 taxa were implicated, with 11 increasing and 4 decreasing disease risk. In addition, five metabolites were causally linked to EC (two risk-related and three protective), and six to EAC (five risk-related and one protective). Mediation analyses revealed that specific metabolites partially mediated the effects of GM on both EC and EAC. Conclusions: Our findings provide genetic evidence for a causal GM-metabolite-cancer axis in EC pathogenesis. These results highlight the role of circulating metabolites as potential intermediaries linking GM to EC and EAC, and suggest new avenues for biomarker discovery and microbiome-targeted interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.